Investment report on Somaxon Pharmaceuticals

Jun 25 2010

MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/SOMX

Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. On March 18, 2010, the food and drug administration (FDA) notified the Company that it approved its New Drug Application (NDA) for Silenor (doxepin) 3 milligram and 6 milligram tablets for the treatment of insomnia characterized by difficulty with sleep maintenance. Silenor is an oral tablet formulation of doxepin at strengths of three milligram and six milligram. Doxepin has been marketed from 75 milligram to 300 milligram per day and is indicated for the treatment of depression and anxiety. The Company's clinical development program for Silenor included four Phase III clinical trials, and the primary efficacy endpoint achieved statistical significance in each trial. 

Message Board Search for SOMX: http://www.boardcentral.com/boards/SOMX

In the report, the analyst notes:

"For the first quarter of 2010, net loss applicable to common stockholders was $4.2 million, or $0.16 per share, compared with $4.5 million, or $0.25 per share, for the first quarter of 2009. As a development stage pharmaceutical company, SOMX had no revenues during the first quarter of 2010.  

"Silenor is the first and only non-scheduled prescription sleep aid that is proven to provide patients with a full night's sleep, including sleep into the 7th and 8th hour. Silenor is approved for use in people with chronic (long-term) or transient (short-term) insomnia characterized by difficulty with sleep maintenance. Silenor can be used for as long as recommended by the treating physician, and is approved for use in adults and in the elderly."